Compare · A vs ASTC
A vs ASTC
Side-by-side comparison of Agilent Technologies Inc. (A) and Astrotech Corporation (DE) (ASTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ASTC operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $43.71B, about 2921.2x ASTC ($15.0M).
- ASTC has hit the wire 7 times in the past 4 weeks while A has been quiet.
- A has more recent analyst coverage (25 ratings vs 0 for ASTC).
- Company
- Agilent Technologies Inc.
- Astrotech Corporation (DE)
- Price
- $156.25+1.85%
- $7.73+0.00%
- Market cap
- $43.71B
- $15.0M
- 1M return
- -
- +4.39%
- 1Y return
- -
- +55.53%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 0
- 7
- Recent ratings
- 25
- 0
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Latest A
- Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
- Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
- Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
- Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
- Jefferies resumed coverage on Agilent with a new price target
- Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
- Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
- Senior Vice President Kirkwood Jonah Prevost covered exercise/tax liability with 30 shares, decreasing direct ownership by 0.21% to 14,108 units (SEC Form 4)
- Bernstein resumed coverage on Agilent with a new price target
- Agilent Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest ASTC
- Astrotech Corporation (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Astrotech Corporation (DE)
- SEC Form 424B5 filed by Astrotech Corporation (DE)
- ASTROTECH APPOINTS STRATEGIC ADVISORY BOARD TO HELP ADVANCE LUNAR RESOURCES AND INFRASTRUCTURE INITIATIVE
- Astrotech Announces Plans for LP&L to Develop a Commercial Lunar Electric Utility
- Amendment: SEC Form 10-Q/A filed by Astrotech Corporation (DE)
- Gravitics Appoints Philip Wong as Chief Financial Officer
- Chief Operating Officer Badugu Nihanth was granted 5,000 shares (SEC Form 4)
- Astrotech Corporation (DE) filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- ASTROTECH APPOINTS MATT KREPS TO BOARD OF DIRECTORS